HARCP

HEROIN ADDICTION AND
RELATED CLINICAL PROBLEMS

The official journal of
EUROPAD - European Opiate Addiction Treatment Association
WFTOD - World Federation for the Treatment of Opioid Dependence
Editor: Icro Maremmani, MD - Pisa, Italy, EU
Associate Editors:
Thomas Clausen, MD - Oslo, Norway
Pier Paolo Pani, MD - Cagliari, Italy, EU
Marta Torrens, MD - Barcelona, Spain, EU
Statistical Editor:
Mario Miccoli, PhD - Pisa, Italy, EU

HARCP Archives

Browse by volume Browse by article Published Ahead
of Print
 

Heroin Addiction and Related Clinical Problems: 2023, 25, N6 (pages: 25 - 28)

Are urine tests within opioid agonist treatment a justified practice?

Baud C.-A., Schmitt-Koopmann C., Junod V., Dickson C., Brülisauer L., Broers B., and Simon O.

Summary: In most countries, urine tests are required for opioid agonist treatment (OAT). Whilst Swiss federal law does not require urine tests as part of OAT follow-up, several Swiss cantons either request or recommend them. This article presents a viewpoint previously published in a French and a French/German paper supported by Swiss associations of addiction professionals. The article questions the legal and medical justification for such tests in connection with OAT. The flaws of urine testing as a clinical assessment tool are discussed, as well as the potentially negative impact on the therapeutic process for opioid dependence. In line with a person-centred approach, recommendations include removing the obligation from any remaining legislation and limiting tests to situations where the person in treatment has requested them.

 

AU-CNS Associazione per l’Utilizzo delle Conoscenze Neuroscientifiche a fini Sociali
Association for the Application of Neuroscientific Knowledge to Social Aims
Via XX Settembre, 83 – 55045 PIETRASANTA (Lucca) - Italy
P. IVA 01681650469 – Codice Fiscale 94002580465 Reserved Area
Tel/Phone: 0584 - 790073 - Email: info@heroinaddictionrelatedclinicalproblems.org
Start of page